MIXT IV Spa: Bringing Modern IV Therapy to Los Alamitos & Surrounding Cities
MIXT IV Spa, a Modern Health and Wellness Destination, is Excited to Announce Its Opening in Los Alamitos, Proudly Serving...
Staff
Interactive Strength Inc. (Nasdaq:TRNR) Updates FAQ’s About Increased Guidance to $80M Pro Forma Revenue, Sportstech and TRNR’s $50M Digital Asset Treasury
AUSTIN, TX / ACCESS Newswire / September 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or the "Company"), maker of...
Interactive Strength Inc. (Nasdaq:TRNR) Updates FAQ’s About Increased Guidance to $80M Pro Forma Revenue, Sportstech and TRNR’s $50M Digital Asset Treasury
AUSTIN, TX / ACCESS Newswire / September 11, 2025 / Interactive Strength Inc. (NASDAQ:TRNR) ("TRNR" or the "Company"), maker of...
MentalHealth.com Responds to WHO’s Call: Scaling Global Solutions for Mental Health
One Billion People Living With Mental Health Conditions ATLANTA, GA / ACCESS Newswire / September 11, 2025 / The World...
MentalHealth.com Responds to WHO’s Call: Scaling Global Solutions for Mental Health
One Billion People Living With Mental Health Conditions ATLANTA, GA / ACCESS Newswire / September 11, 2025 / The World...
Femasys Expands FemSperm™ Product Line with New Insemination Prep Kit to Broaden Gynecology-Based Access to FemaSeed®
-- Following the Setup Kit, the Insemination Kit completes the sperm preparation portion of FemSperm enabling gynecology call point activation...
Bausch Health Completes Acquisition of DURECT Corporation, Expanding Late-stage Liver Disease Portfolio
The transaction adds larsucosterol, an FDA Breakthrough Therapy for alcohol-associated hepatitis with a registrational Phase 3 clinical trial in development,...
Athira Pharma Announces Reverse Stock Split
BOTHELL, Wash., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (“Athira” or “Company”) (NASDAQ: ATHA), a clinical stage biopharmaceutical...
Nacuity Pharmaceuticals Announces Positive Data from Clinical Trial Evaluating NPI-001 to Treat Retinitis Pigmentosa Associated with Usher Syndrome
NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was...
RETRANSMISSION: NanoViricides to Present at the Life Science Executive Partnering (LSX) Congress in Boston on September 17, 2025
This release is being retransmitted for extra exposure to downstream sites. SHELTON, CT / ACCESS Newswire / September 11, 2025...
Anteris Technologies Global Corp. Announces Postponement of Special Meeting of Stockholders
MINNEAPOLIS and BRISBANE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR),...
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
SAN DIEGO, CA / ACCESS Newswire / September 11, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a...
GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)
No decline in lung function observed at 6-week interim analysis builds upon positive safety and biomarker data Phase 2a study fully...
RenovoRx CEO Shaun Bagai to Present at iAccess Alpha Virtual Best Ideas Fall Investment Conference 2025 on September 16th
MOUNTAIN VIEW, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a life sciences...
Avel eCare’s Dr. Kelly Rhone to Speak on Rural Health Panel at ATA Annual Conference
SIOUX FALLS, SD / ACCESS Newswire / September 11, 2025 / Avel eCare today announced that Dr. Kelly Rhone, Chief...
Profusa Adopts NVIDIA-Powered Technology to Build AI-Driven Insight Portal for Continuous Biomarker Monitoring
Company expects early 2026 rollout in EEA; physician portal combines Lumee™ oxygen monitoring with NVIDIA NeMo to deliver AI-driven clinical...
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor 1Filing based on four Phase 3...
Lexicon Pharmaceuticals to Present Additional Clinical Data on Pilavapadin at Three Upcoming Medical Meetings
Presentations collectively highlight pilavapadin’s potential to improve pain management care for patients with diabetic peripheral neuropathic pain (DPNP) Breadth of...
Intercept Announces Voluntary Withdrawal of OCALIVA® for Primary Biliary Cholangitis (PBC) from the US Market; US Clinical Trials Involving Obeticholic Acid Placed on Clinical Hold
MORRISTOWN, N.J., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc., a wholly owned biopharmaceutical subsidiary of Alfasigma S.p.A., today...
SELLAS Life Sciences Group Announces Exercise of Existing Warrants Held by a Current Institutional Investor for $23.6 Million in Gross Proceeds
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...